

REVIEW

EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management

Chi Young Ok¹, Ling Li^{1,2} and Ken H Young^{1,3}

Epstein–Barr virus (EBV) is a ubiquitous herpesvirus, affecting >90% of the adult population. EBV targets B-lymphocytes and achieves latent infection in a circular episomal form. Different latency patterns are recognized based on latent gene expression pattern. Latent membrane protein-1 (LMP-1) mimics CD40 and, when self-aggregated, provides a proliferation signal via activating the nuclear factor-kappa B, Janus kinase/signal transducer and activator of transcription, phosphoinositide 3-kinase/Akt (PI3K/Akt) and mitogen-activated protein kinase pathways to promote cellular proliferation. LMP-1 also induces BCL-2 to escape from apoptosis and gives a signal for cell cycle progression by enhancing cyclin-dependent kinase 2 and phosphorylation of retinoblastoma (Rb) protein and by inhibiting p16 and p27. LMP-2A blocks the surface immunoglobulin-mediated lytic cycle reactivation. It also activates the Ras/PI3K/Akt pathway and induces Bcl-xL expression to promote B-cell survival. Recent studies have shown that ebv-microRNAs can provide extra signals for cellular proliferation, cell cycle progression and anti-apoptosis. EBV is well known for association with various types of B-lymphocyte, T-lymphocyte, epithelial cell and mesenchymal cell neoplasms. B-cell lymphoproliferative disorders encompass a broad spectrum of diseases, from benign to malignant. Here we review our current understanding of EBV-induced lymphomagenesis and focus on biology, diagnosis and management of EBV-associated B-cell lymphoproliferative disorders.

Experimental & Molecular Medicine (2015) 47, e132; doi:10.1038/emm.2014.82; published online 23 January 2015

INTRODUCTION

Epstein–Barr virus (EBV) is a ubiquitous double-stranded DNA virus that belongs to the family Herpesviridae and subfamily Gammaherpesvirinae. Gammaherpesvirinae includes two important human gammaherpesviruses, EBV (also known as human herpesvirus 4) and Kaposi's sarcoma-associated herpes virus (also known as human herpesvirus 8 (HHV8)). EBV is a γ -1 herpes virus, characterized by a tropism for B-lymphocytes with latent infection in the host and the capacity for transforming B-lymphocytes. More than 90% of the population worldwide carry the virus. EBV was first discovered in a Burkitt lymphoma (BL)–derived cell line by Michael Epstein, Yvonne Barr and Bert Achong in 1964 by electron microscopy.¹ Almost all EBV-seropositive hosts shed virus in the saliva, and infection occurs when an EBV-naive person is exposed to EBV-rich saliva.² Oropharyngeal epithelium is an entry point for EBV via the immunoglobulin (Ig) A–EBV complex to IgA receptors on the epithelium, and active

viral replication (lytic infection) occurs there.^{3,4} The virus spreads out from the infected cells and directly infects nearby B-lymphocytes via viral enveloping of glycoprotein gp 350 to the B-lymphocyte surface molecule CD21.⁵ Penetration of the virus requires interaction between viral gp 42 (which makes a complex with gH and gL) and HLA-DR on B-lymphocytes.⁶ Indirectly, the infected epithelium can transmit the virus to B-lymphocytes. In infected B-cells, the linear genome circularizes and remains latent as episome in the nucleus (latent infection). Only a small proportion of the latently infected B-lymphocytes undergo viral replication spontaneously.

The EBV genome is a linear-shaped DNA of approximately 172 kb, encoding approximately 100 viral proteins. At both termini of the linear genome, there are variable numbers of 0.5-kb tandem repeats.⁷ In the lytic cycle, most of the EBV viral proteins are expressed but are kept in check by the host immune response. In contrast, only a handful of genes are expressed during latent infection: six EBV nuclear antigens

¹Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ²Department of Medical Oncology, University of Zhengzhou School of Medicine, Zhengzhou, China and ³The University of Texas School of Medicine, Graduate School of Biomedical Sciences, Houston, TX, USA

Correspondence: Dr KH Young, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA.

E-mail: khyoung@mdanderson.org

Received 11 September 2014; accepted 1 October 2014

(EBNA-1, 2, 3A, 3B, 3C and LP), three latent membrane proteins (LMP-1, 2A and 2B), and non-coding RNA (EBV-encoded small RNA (EBER)-1 and 2). EBNA-1 binds to viral DNA and maintains its episomal form.⁸ EBNA-2 transactivates LMP-1 via interaction with the cellular DNA-binding protein κ or PU.1.⁹ Because LMP-2B shares the EBNA-2 responsive promoter with LMP-1, EBNA-2 can also upregulate LMP-2B.¹⁰ Three different isoforms exist in EBNA-3, and they inhibit EBNA-2-mediated upregulation of LMP-1.¹¹ EBNA-LP enhances the function of EBNA-2 to transactivate LMP-1. LMP-1 is oncogenic *in vivo* without expression of the other EBV gene and functionally mimics CD40, which is involved in B-cell activation and proliferation.^{12,13} It is a six-transmembrane integral protein with a 200 amino-acid C-terminal cytoplasmic tail. This tail includes two important domains, C-terminal activation region 1 (CTAR1) and CTAR2. The transmembrane domain provides a platform for LMP-1 oligomerization, which results in constitutive activation of the molecule. Constitutively activated LMP-1 allows CTAR1 and CTAR2 to interact with downstream molecules, such as tumor necrosis factor receptor-associated factors (TRAFs) to activate the nuclear factor-kappa B (NF- κ B) pathway.¹⁴ LMP-1 also activates the phosphoinositide 3-kinase (PI3K)/Akt pathway, c-Jun N-terminal kinase/AP-1, bcl-2, and A20, which inhibits p53-associated cell death.^{15–19} Cell cycle dysregulation can be caused by LMP-1 (Figure 1).²⁰

LMP-2 has two isoforms, LMP-2A and LMP-2B. The genes for LMP-2A and LMP-2B span across the terminal repeats, so they are transcribed only when EBV is in circular form.²¹ They share 12 membrane-spanning domains and a 27 amino-acid C-terminal cytoplasmic domain. Both LMP-2A and LMP-2B have EBNA-2 responsive promoters that have sites for RBP- κ and PU.1, but their promoters are 3-kb apart.¹⁰ LMP-2A has an N-terminal cytoplasmic tail that binds to Lyn via SH2-binding

motif and Syk via ITAM (immunoreceptor tyrosine-based activation motif).²² However, the N-terminal cytoplasmic domain in LMP-2A is lacking in LMP-2B.²³ In B-lymphocytes, surface Ig (sIg)-mediated EBV lytic reactivation from latent infection can be induced via those protein tyrosine kinases.²⁴ However, LMP-2A blocks the sIg-mediated lytic reactivation and therefore acts as a dominant-negative inhibitor of the sIg-associated protein tyrosine kinases. LMP-2A increases Bcl-xL expression and activates the Ras/PI3K/Akt pathway to mediate B-cell survival.^{25,26} It also potentiates MYC-induced hyperproliferation by downregulating p27 in a proteasome-dependent manner.²⁷ LMP-2B modulates LMP-2A *in vitro*, but its function *in vivo* is largely unknown.²⁸ The function of EBERs is not clear, but EBERs are transcribed up to 10^7 copies per cell in all forms of EBV latency.²⁹ Currently, *in situ* hybridization for EBER is the most reliable method for morphological detection of latent EBV infection.³⁰ On the basis of the latent gene expression, three different latency patterns are recognized. In type I latency, EBER and EBNA-1 are expressed. In type II latency, LMP-1, LMP-2A and LMP-2B are additionally expressed. In type III latency, all latent genes are expressed. Particular diseases with specific latency patterns are shown in Table 1.

Recent studies have expanded our knowledge of EBV microRNAs (miRNAs). EBV was the first virus in which miRNA was found.³¹ At the time of writing, 44 mature ebv-miRs have been recognized (Sanger miRBase library, release 20.0, <http://www.mirbase.org/cgi-bin/query.pl?terms=EBV>). Two independent ebv-miRNAs are known. The ebv-miR-BHRF1 family is located within the introns of BHRF1, and the ebv-miR-BART family is located in the introns of the BamHI-A region rightward transcript (BART) in two separate clusters.^{32,33} Viral miRNAs can maintain viral latency, evade host immune response and inhibit lytic cycle reactivation.^{34–36}




Figure 1 LMP-1 and LMP-2 and downstream signal transduction.

A recent study has shown that multiple cellular pathways, including p53 feedback loop, B-cell signaling, oxidative stress response and apoptosis pathways, could potentially be targeted by ebv-miRNAs.³⁷ More specifically, ebv-miR-BHRF1 can promote cell cycle progression/proliferation and prevent apoptosis.³⁸ ebv-miR-BART5 degrades a pro-apoptotic protein and p53-upregulated modulator of apoptosis.³⁹ Cellular miRNAs can be dysregulated by EBV latent proteins. Mir-34a and mir-155 can be induced by LMP-1 through the NF- κ B pathway.^{40,41} EBNA-2 can enhance the NF- κ B and Akt pathways by inducing miR-146a and downregulating miR-21, respectively.⁴²

DIAGNOSIS, DIFFERENTIAL DIAGNOSIS AND CLASSIFICATION OF EBV+ LYMPHOPROLIFERATIVE DISORDERS

Benign disorders

Infectious mononucleosis (IM) lymphadenitis. IM lymphadenitis is an acute, self-limited lymphadenitis caused by EBV infection. In the United States, most young adults are exposed to EBV, and about half of them acquire IM. Patients generally have fever, pharyngitis, lymphadenopathy and splenomegaly. Complications are rare, but splenic rupture, upper airway obstruction, severe hematologic cytopenia or hepatitis can occur. Although complications happen, these symptoms can be resolved without sequelae. Results for the agglutination-based monospot test using horse erythrocytes are positive. EBV-specific antibodies such as IgM and IgG anti-viral capsid antigen antibodies or anti-EA antibodies appear, and circulating lymphocytes with abundant pale blue cytoplasm and large

nucleus are increased. The lymph node architecture is partially effaced by paracortical hyperplasia, follicular hyperplasia or sinus histiocytosis. Paracortical expansion is the most common pattern, usually composed of a mixture of small lymphocytes, immunoblasts, plasma cells and histiocytes. Immunoblasts can form a sheet, mimicking diffuse large B-cell lymphoma (DLBCL) (Figure 2). By immunohistochemistry, CD20 highlights B-cell-rich follicles and B-immunoblasts in the paracortex. CD3 shows T-cells, mature lymphocytes and T-immunoblasts in the paracortex. *In situ* hybridization for EBER shows numerous EBV-infected cells. Ig genes and/or T-cell receptor genes show a polyclonal pattern.

EBV-positive mucocutaneous ulcer. EBV-positive mucocutaneous ulcer is a unique clinicopathological entity, first described by Dojcinov *et al.*,⁴³ who reported it in 26 patients either with immunosuppression caused by azathioprine, methotrexate or cyclosporine A given for various autoimmune diseases or with age-related immunosenescence. The median patient age was 77 years (range 24–101 years), with a slight female predominance. Interestingly, all immunosuppressed patients who had available outcome data achieved complete remission when immunosuppressants were reduced. Patients with age-related immunosenescence showed spontaneous remission or relapsing and remitting clinical course when no therapy was given. All patients with age-related immunosenescence who underwent chemotherapy and/or radiotherapy achieved complete remission. Most importantly, none of the reported patients died of the disease irrespective of treatment.

Table 1 Epstein–Barr virus latency in selected EBV-driven lymphoproliferative disorders

Latency	Gene products	Disease
I	EBER, EBNA-1	BL, PBL, PEL
II	EBER, EBNA-1, LMP-1, LMP-2A, LMP-2B	CHL, EBV+ DLBCL of the elderly, PBL (subset), LyG (subset), PTLD (subset)
III	EBER, EBNA-1, LMP-1, LMP-2A, LMP-2B, EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C	IM, DLBCL with CI, LyG, PTLD, EBV+ DLBCL of the elderly (subset)

Abbreviations: BL, Burkitt lymphoma; CHL, classical Hodgkin lymphoma; DLBCL, diffuse large B-cell lymphoma; DLBCL with CI, diffuse large B-cell lymphoma associated with chronic inflammation; EBER, Epstein–Barr virus encoded small RNA; EBNA, Epstein–Barr virus nuclear antigen; IM, infectious mononucleosis; LMP, latent membrane protein; LyG, lymphomatoid granulomatosis; PBL, plasmablastic lymphoma; PEL, primary effusion lymphoma; PTLD, posttransplant lymphoproliferative disorder.




Figure 2 Infectious mononucleosis. (a) The paracortex of a lymph node is expanded by proliferation of immunoblasts. Hematoxylin and eosin, $\times 400$. (b) *In situ* hybridization for EBER shows numerous positive cells, $\times 400$.

This disorder occurs as isolated, well-demarcated ulcers in the oropharyngeal mucosa, skin and gastrointestinal tract. This lesion is characterized by a polymorphous infiltrate composed of lymphocytes, immunoblasts, plasma cells, histiocytes and eosinophils with atypical large B-cell blasts resembling Hodgkin Reed–Sternberg (HRS) cells. Plasmacytoid apoptotic cells were consistently observed in all cases, and angioinvasion was not uncommonly seen (23%). Immunohistochemistry shows a mixture of B- and T-cells in the polymorphic infiltrates. The HRS-like cells were of B-cell origin (CD20⁺, CD79a⁺, PAX5⁺, Oct-2⁺ and Bob.1⁺) with CD30 and CD45 expression in most cases. The intermixed T-cells were predominantly CD4-positive helper T-cells. *In situ* hybridization for EBER was positive in all cases, which accentuates demarcation of the lesion from the surrounding tissue. The EBER-positive cells co-expressed CD20 and PAX-5, showing the B-cell nature. Most cases showed at least phase II EBV latent infection with LMP-1 expression. Because of the presence of immunoblasts and HRS-like cells, classical Hodgkin lymphoma (CHL) or DLBCL can be misdiagnosed. Clonality tests might not help in distinguishing EBV-positive mucocutaneous ulcer from DLBCL or from T-cell lymphoma, because about 40% of cases showed clonal Ig gene rearrangement and T-cell receptor gene rearrangement, respectively.

Gray disorders

Chronic active EBV (CAEBV) disease, B-cell type. CAEBV disease is an uncommon EBV-associated lymphoproliferative disorder affecting B-cells, T-cells or NK cells. It is currently defined as a severe progressive illness of >6 months that begins as a primary EBV infection or is associated with heavily elevated anti-EBV viral capsid antigen IgG \geq 1:5120 or anti-EBV early antigen IgG \geq 1:640 or markedly elevated EBV DNA in the peripheral blood with histological evidence (lymphocytic infiltration) of major organ involvement and increased EBER or proteins in the affected tissues in patients without an immunosuppressive condition.⁴⁴ It was first described by Straus as ‘the chronic mononucleosis syndrome’ to differentiate this disease from chronic fatigue syndrome.⁴⁵ The major organ involvement denotes lymphadenitis, persistent hepatitis, splenomegaly, interstitial pneumonia, hypoplasia of the bone marrow or uveitis. The etiology of CAEBV is uncertain.⁴⁶ EBV stimulates secretion of a variety of cytokines and chemokines in both EBV-infected cells and non-infected cells. The current recommendation is to specify the nature of the EBV-infected cells as being B-cells, T-cells or NK cells. In this review, we focus only on CAEBV, B-cell type. For T-cell or NK cell types, please consult the article by Kimura *et al.*⁴⁷

Most cases of CAEBV have been reported in Asia, and almost all of the Asian cases have been of T-cell or NK cell origin.⁴⁷ Unlike for Asian CAEBV, the most common type (57.9%) of CAEBV in United States is of B-cell origin.⁴⁴ Of the 11 reported cases, 7 were men and 4 were women, with a median age at onset of 20 years (range 5–51 years). The ethnic distribution was eight white patients, one black, one Hispanic and one Asian. The most common signs and symptoms were

lymphadenopathy (100%), followed by splenomegaly (72.7%), hypogammaglobulinemia (54.5%), fever and hemophagocytosis (45.5%), hepatitis (36.4%), hepatomegaly, central nervous system disease, peripheral neuropathy, interstitial pneumonia and pancytopenia (27.3%). Histological findings of CAEBV were not characteristic. Instead, prominent T-cell infiltrates and fewer numbers of EBER⁺ and CD20⁺ lymphocytes were seen in the affected tissues. Clonal rearrangements of the IgH genes were found in five (62.5%) of the eight tested cases. Anti-EBV viral capsid antigen IgG titer was elevated (\geq 1:5120) in 50% of the 10 tested cases. More than half (56%) of the patients had decreased number of CD19⁺ B-cells compared with healthy individuals. Cytokine levels of interleukin-6, interleukin-10, tumor necrosis factor- α , and interferon- γ were significantly elevated in CAEBV patients compared with control patients. The 5-year overall survival rate for patients with B-cell CAEBV was 73, but 64% of the patients eventually died.

HHV8- and EBV-associated germinotropic lymphoproliferative disorder. HHV8- and EBV-associated germinotropic lymphoproliferative disorder is a very rare disease that was first described by Du *et al.*,⁴⁸ reporting three patients. HHV8 latency-associated nuclear antigen (LANA) encoded by viral ORF 73 and EBER are defining features of this lesion, but the pathogenetic role of these viruses has not been fully investigated. Histologically, lymph node architecture is partially effaced with nodular proliferation of plasmablasts or bizarre anaplastic cells. The plasmablasts are not found in the mantle zone or the interfollicular area. The typical immunophenotype is CD10⁻, CD20⁻, CD30^{+/-}, CD38^{+/-}, CD79a⁻, CD138⁻, BCL2⁻, BCL6⁻, MUM1⁺, HHV8⁺ and EBER⁺. Expression of a monotypic Ig light chain indicates a B-cell origin of the disease. This lesion shows a polyclonal or oligoclonal pattern of Ig gene rearrangement and hence is considered a lymphoproliferative disorder and not a lymphoma. Although it shows favorable outcome after chemotherapy or radiotherapy, there is little information available to fully characterize its clinical behavior.

Malignant disorders

Diffuse large B-cell lymphoma. EBV-positive DLBCL of the elderly. EBV-positive DLBCL of the elderly is defined as an EBV-positive monoclonal large B-cell lymphoproliferative disorder in immunocompetent patients aged >50 years.⁴⁹ Cases of lymphomatoid granulomatosis (LyG), plasmablastic lymphoma (PBL), primary effusion lymphoma, DLBCL associated with chronic inflammation or IM are excluded. Table 2 summarizes the morphological, immunophenotypical and genetic findings in the major EBV⁺ lymphoid malignancies. The EBV-positive DLBCL of the elderly was originally described by Oyama *et al.*⁵⁰ in 2003, emphasizing similarity to immunodeficiency-related lymphoproliferative disorder in immunocompetent elderly patients. An imbalanced immune system due to aging is postulated to promote lymphomagenesis. Of note, EBV positivity is generally determined to indicate positive expression of EBER in lymphoma cells, but a

consensus for its cutoff has not been established (Figure 3).⁵¹ It is more common in Asian countries (8–11%) than in the Western hemisphere (2–4%), with variable EBV cutoffs.^{52–57} Median patient age is 71 years (range 50–91 years), with a male to female ratio of 1.4 to 1. Epidemiological differences are seen in different geographic pockets. For example, EBV-positive DLBCL is more commonly reported in East Asia compared with Western countries. Mexican patients tend to be younger, to mostly have nodal involvement and to be less likely to express EBNA-2.⁵³

World Health Organization (WHO) recognizes two main morphological subtypes, polymorphous and large-cell lymphoma (monomorphic). The polymorphous subtype demonstrates a range of B-cell maturation with a variable component of reactive elements. The monomorphic subtype shows a monotonous sheet of large transformed B-cells. Recently, Montes-Moreno *et al.*⁵⁸ subdivided the polymorphous subtype into three further subgroups. However, morphological distinction does not indicate prognostic importance. The lymphoma cells express B-cell markers. CD30 is expressed in about 40% of

Table 2 Morphologic, immunophenotypic and genetic findings helpful for differential diagnoses

Disease	Morphology	Immunophenotype	Genetic
EBV+DLBCL of the elderly	Polymorphic and monomorphic subtypes	CD20 ⁺ , CD30 ^{+/–} , EBER ⁺ , LMP-1 ⁺	<i>BCL2</i> , <i>BCL6</i> , <i>C-MYC</i> and <i>TP53</i> usually not rearranged
DLBCL with CI	Typical DLBCL morphology	CD20 ⁺ , CD138 [–] , but CD20 [–] , CD138 ⁺ in cases with plasmacytic differentiation	<i>TP53</i> mutation
PBL	Sheets of immunoblasts or plasmablasts	CD20 [–] , CD138 ⁺ , MUM1 ⁺ , EMA ⁺ , EBER ⁺ , HHV8 [–]	<i>MYC</i> rearrangement
PEL	Immunoblastic or anaplastic cells in cytopsin, plasmablastic or immunoblastic in tissue section	CD45 ⁺ , CD20 [–] , CD79a [–] , sig [–] , CD30 ^{+/–} , CD138 ^{+/–} , CD38 ^{+/–} , EMA ^{+/–} , HHV-8 ⁺ , EBER ⁺ , LMP-1 [–]	<i>BCL2</i> , <i>BCL6</i> and <i>C-MYC</i> usually not rearranged
LyG	Angioinvasion, angiodestruction, polymorphic background with several large atypical lymphoid cells. HRS-like cells present	CD20 ⁺ , CD30 ^{+/–} , CD15 [–] , EBER ⁺ , LMP-1 ^{–/±}	Monoclonal immunoglobulin heavy chain gene rearrangement in grade 2 or 3
BL	Starry sky pattern, sheets of intermediate-sized lymphoid cells with round-to-oval nucleus	CD10 ⁺ , CD20 ⁺ , BCL-2 [–] , BCL-6 ⁺ , Ki-67 100%	t(8;14), t(2;8), t(8;22)

Abbreviations: BCL, B-cell lymphoma; BL, Burkitt lymphoma; DLBCL, diffuse large B-cell lymphoma; DLBCL with CI, diffuse large B-cell lymphoma associated with chronic inflammation; EBV, Epstein–Barr virus encoded small RNA; EMA, epithelial membrane antigen; HHV8, human herpesvirus 8; LMP, latent membrane protein; LyG, lymphomatoid granulomatosis; MUM1, multiple myeloma oncogene 1; PBL, plasmablastic lymphoma; PEL, primary effusion lymphoma.




Figure 3 EBV-positive diffuse large B-cell lymphoma of the elderly. (a) The lymph node is completely effaced by a homogeneous population of large lymphoma cells. Hematoxylin and eosin, ×400. (b) CD20 stain shows numerous positive B-cells, ×400. (c) Ki-67 stain shows a high proliferation index, ×400. (d) *In situ* hybridization for EBV shows positive lymphoma cells, ×400.

cases. Expression levels of NF- κ B component p50 and phosphorylated signal transducer and activator of transcription 3 (pSTAT3) are more commonly seen compared with EBV-negative DLBCL. LMP-1 and EBNA-2 are expressed in $>2/3$ and about $1/3$ of cases, respectively, hence phase II or III latency patterns. Gene expression profiling showed that EBV-positive DLBCL is molecularly distinct from EBV-negative DLBCL. The gene set enrichment assay demonstrated an enhanced Toll-like receptor signaling pathway (which has many similarities to the NF- κ B pathway) and the Janus kinase(JAK)-STAT pathway.⁵² Clonal rearrangement of the Ig gene is seen in most cases. Contrary to prior reports, mostly from Asian countries, of EBV-positive DLBCL with worse prognosis, a large cohort study from Western countries did not show adverse outcome in DLBCL with single expression of EBER. However, patients with co-expression of CD30 and EBER had a worse prognosis.⁵² Current treatment recommendation for DLBCL does not change for EBV positivity. EBV-positive DLBCL patients respond poorly and show variations to standard R-CHOP regimen with regard to ethnic background, CD30 expression, geographical distribution and oncogenic signaling activation. Adoptive immunotherapy against EBV latency antigens and implementation of oncogenic signaling target inhibitors targeting CD30, Btk or NF- κ B components may improve outcome.

DLBCL associated with chronic inflammation. DLBCL with chronic inflammation is a B-cell neoplasm, mostly associated with EBV infection, arising in patients with a long-standing chronic inflammation, such as pyothorax, chronic osteomyelitis, metallic implant or chronic skin ulcer.⁵⁹ The prototype of this lymphoma is pyothorax-associated lymphoma, first described in the English literature in 1987 by Iuchi *et al.*,⁶⁰ who reported three cases during the period from 1971 to 1985. In an expanded series of 106 patients with pyothorax-associated lymphoma by the same study group, 93 (88%) cases were DLBCL, four cases (4%) were lymphoplasmacytic lymphoma and four cases (4%) were peripheral T-cell lymphoma. The immunophenotype could not be determined in five cases (4%).⁶¹ In this series, 80% of the patients had pyothorax resulting from artificial pneumothorax for the treatment of pulmonary tuberculosis, 17% had tuberculous

pleuritis and 3% had pyothorax not associated with tuberculosis. Median age was 64 years (range 46–82 years), with a male-to-female ratio of 12.3:1. The median latency of developing DLBCL with chronic inflammation after pyothorax was 37 years (range 20–64 years). Common symptoms were chest or back pain, fever, tumor or swelling of chest wall, and respiratory symptoms such as productive cough with or without hemoptysis and dyspnea. The tumor is mostly confined to the pleura with invasion to the adjacent tissue, such as lung, diaphragm, ribs and mediastinum. Metastasis is uncommon. About half of the cases have large (>10 cm) tumor. Most cases are of lower (I/II) stage. Peripheral blood and bone marrow are usually spared.

Morphology is typical for DLBCL. The abutting pleural tissue shows extensive fibrous thickening with sparse inflammatory cells, including lymphocytes and plasma cells. Most lymphoma cells are positive for CD20 and CD79a but can be negative in cases with plasmacytic differentiation. MUM-1 and CD138 are positive in such cases. EBER and EBNA-2 are positive in most cases, illustrating a type III latency program.^{61,62} Clonal rearrangement of the Ig gene is seen in most cases. Comparative genomic hybridization on pyothorax-associated lymphoma tumor samples demonstrated gain of chromosome 8q24, and *MYC* amplification was found by Southern blotting technique.⁶³ Sequencing of the *TP53* gene (exons 5–8) using paraffin-embedded tissue found mutations in $2/3$ of cases, with most being single-nucleotide substitution.⁶⁴ By gene expression profiling, pyothorax-associated lymphoma was shown to be molecularly different from nodal DLBCL, with increased expression of activated B-cell-like signature.⁶⁵ DLBCL with chronic inflammation is an aggressive lymphoma, with 1-, 3- and 5-year survival rates of 49, 27 and 22%, respectively.⁶¹

Plasmablastic lymphoma. PBL is an aggressive lymphoma with immunoblastic morphology but with plasmacytic immunophenotype.⁶⁶ PBL was first described in 1997 by Delecluse *et al.*,⁶⁷ who reported 16 cases mostly in HIV-positive patients. Since the initial description of exclusive occurrence in the oral cavity, PBL has been reported in the gastrointestinal tract, soft tissue, bone, gonads, mediastinum, anal canal and nasal/paranasal area.⁶⁸ PBL was reported in




Figure 4 Plasmablastic lymphoma. (a) Sheets of immunoblasts and/or plasmablasts are present with occasional tingible-body macrophages, imparting a 'starry-sky' pattern. Hematoxylin and eosin, $\times 400$. (b) *In situ* hybridization for EBV shows numerous positive cells, $\times 400$.

patients without HIV infection or immunosuppression with common nodal involvement.^{69,70} Median patient age is about 50 years (range 7–65 years), with a strong male predilection (7:1). Most patients are at advanced stage (stage III/IV) and with intermediate or high International Prognostic Index.

The lymphoma cells typically are of large size with round-to-oval centrally or eccentrically located nucleus, dispersed chromatin, prominent single nucleolus and amphophilic cytoplasm with perinuclear hof (Figure 4). Apoptotic cells with accompanying tingible-body macrophages can be seen, imparting a starry-sky pattern at low magnification. Mitotic figures are frequently seen, consistent with a high Ki-67 proliferation index (90–100%). The lymphoma cells mostly express plasmacytic markers such as CD38 (100%), MUM1 (100%) and CD138 (84%). CD79a is uncommonly expressed (14%); CD20 is virtually not expressed (3%). CD45 expression is seen in 1/3 of the cases. Frequent (80%) expression of epithelial membrane antigen is observed. HHV8 LANA is negative, which is very helpful for differentiating PBL from morphologically similar large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease.⁷¹ Most PBLs are positive for EBER (78%), but with less frequent LMP-1 expression (38%). Hence, the latency pattern is either phase I or II. By FISH, *MYC* rearrangement was seen, with about 50% having *IgH* as the most common partner.⁷² Of note, *MYC* rearrangement was more commonly seen in EBER-positive PBL compared with EBER-negative PBL. Clonal rearrangement of *Ig* gene is seen in most cases. No effective treatment exists for PBL and patients often have a high stage at diagnosis and harbor a poor survival.

Primary effusion lymphoma. Primary effusion lymphoma (PEL) is a rare B-cell neoplasm presenting as a lymphomatous

effusion in pleural, pericardial, or peritoneal cavities without detectable tumor mass, usually in immunosuppressant patients.⁷³ The term PEL was first proposed by Nador *et al.* in 1996 and recognized by WHO in 2001 as a distinct clinicopathologic entity, although it had been recognized as a body cavity-based lymphoma.⁷⁴ It is almost always associated with HHV8 and very commonly associated with EBV. Lymphoma with the same immunophenotype presenting as a solid tumor mass without malignant effusion is regarded as a variant of this entity and is called extracavitary PEL.⁷⁵

Most patients are young or middle-aged homosexual men with HIV infection. PEL can arise in posttransplant patients without HIV infection or rarely in non-immunosuppressant patients.^{76,77} HHV8 is believed pathogenetically to be more important than EBV in PEL, because HHV8 expresses oncogenic cellular homologues with a restricted pattern of EBV infection (mostly phase I).^{78,79} Typical clinical presentation is effusion in a single body cavity without lymphadenopathy or organomegaly. Kaposi sarcoma precedes PEL in about half of the patients. Extracavitary PEL has been reported in lymph nodes and various extranodal locations, most commonly in the gastrointestinal tract.⁸⁰

In cytospin samples, the lymphoma cells show a morphological range from immunoblastic to anaplastic features. Variable numbers of large pleomorphic cells are seen, some of which resemble Reed–Sternberg cells. A prominent Golgi zone adjacent to the nucleus is often present in the lymphoma cells. In tissue sections, the lymphoma cells have round or ovoid to polygonal shape, moderate-to-large amounts of cytoplasm and round to variably indented nuclei with one or more prominent nucleoli (Figure 5). Multinucleated giant




Figure 5 Extracavitary pleural effusion lymphoma. (a) Sheets of immunoblasts and/or plasmablasts are present with frequent mitotic figures. Hematoxylin and eosin, $\times 400$. (b) CD138 stain is positive in most of the lymphoma cells, $\times 400$. (c) *In situ* hybridization for EBV shows many positive cells, $\times 400$. (d) HHV-8 stain is positive in the lymphoma cells, $\times 400$.

tumor cells and lymphoma cells with wreath-like nuclei, resembling hallmark cells in anaplastic large cell lymphoma, can be seen. Mitotic figures are numerous. The lymphoma cells usually express CD45 without expression of pan-B markers (CD19, CD20, CD22 and CD79a) or T/NK cell markers. Surface and cytoplasmic Igs are generally absent. CD30, epithelial membrane antigen, CD38, CD138 and HLA-DR are variably positive. LANA-1 of HHV8 is typically positive with a nuclear dot-like pattern. EBER is positive in about 70% of cases, but LMP-1 is negative. Extracavitary PEL shares a similar immunophenotype but with more common expression of B-cell markers.

Recurrent cytogenetic abnormalities have not been reported. Comparative genomic hybridization of eight PEL cases showed gain of chromosomes 12 and X in three and two cases, respectively, and amplification within the 1q region in two cases.⁸¹ *BCL-2*, *BCL-6* and *MYC* genes were not rearranged, and mutations in *MYC*, *HRAS*, *KRAS*, *NRAS* and *TP53* genes were not found.⁷⁴ Clonal rearrangement of the Ig gene is seen in most cases and can be used for determining lineage. Gene expression profiling showed that PEL is distinct from non-Hodgkin lymphomas in immunocompetent patients and from AIDS-related lymphomas. The study also showed that PEL is in the differentiation stage of plasmablasts, because the gene expression profile showed features of immunoblasts, between EBV-transformed lymphoblastoid cell lines or AIDS immunoblastic lymphoma and plasma cells from multiple myeloma cell lines.⁸² Effective treatment lacks in PEL, and patients often demonstrate a dismal outcome.

Lymphomatoid granulomatosis. LyG was first reported by Liebow *et al.*⁸³ in 1972 as nodular and granulomatous lesions. It is a rare EBV-driven angiocentric and angiodestructive lymphoproliferative disorder with a spectrum of clinical manifestation depending on the number of EBER-positive abnormal cells.⁸⁴ It usually affects adults, typically in the fourth to sixth decade of life, with a male predominance (male-to-female ratio >2:1). Patients with congenital immunodeficiency, immunosuppressed patients or those with autoimmune disease are at increased risk. It is generally an extranodal disease. Lung involvement is almost always present, followed by kidney, skin and central nervous system. Lymph node and spleen are usually not involved at the initial presentation but can be involved when the disease has progressed. Lung involvement is usually bilateral, and middle/lower lobes are preferred sites. Clinically, it can present with fever, productive cough and dyspnea, mimicking infection. Other symptoms include malaise, weight loss, fatigue, variable neurological symptoms and gastrointestinal symptoms.

Histologically, LyG is characterized by a small number of EBER-positive intermediate-to-large atypical B-cells in a background of T-lymphocytes, plasma cells and histiocytes. Angioinvasion and angiodestruction are commonly seen. Although the name implies granulomatous reaction, well-formed granulomas are generally absent. Poorly formed granulomas can be seen in subcutaneous tissue.⁸⁵ EBER-

positive B cells have immunoblastic or pleomorphic morphology, resembling mononuclear Hodgkin cells. However, classic binuclear Reed–Sternberg cells are not present. The EBER-positive atypical B-cells are positive for CD20, with variable expression of CD30, but negative for CD15. CD4-positive T-cells are more predominant than CD8-positive T-cells in the background. Available data regarding latent EBV infection pattern in LyG showed latency II or III in most cases.⁸⁶

LyG can be graded based on the number of EBER-positive atypical B-cells. Grade 1 LyG typically has only a few EBER-positive atypical B-cells (<5 per high-power field), and they might be absent in some cases. Grade 2 LyG typically has 5–20 EBER-positive atypical B-cells per high-power field, and grade 3 LyG usually has >50. Grade 3 LyG is usually regarded as a DLBCL equivalent because of its aggressive clinical behavior and therapeutic options similar to those for DLBCL. On the other hand, grade 1 and 2 LyG usually have an indolent course. However, one should be aware that about 15% of lower grade LyG can progress to malignant lymphoma.⁸⁷ PCR analysis for Ig heavy chain gene rearrangement demonstrated a monoclonal pattern.⁸⁸ Grade III LyG patients are treated with similar regimens used for DLBCL and DA-EPOCH-R has been reported to be effective with 66% complete remission. Interferon- α was reported to be effective in nearly 60% grade I and II LyG patients; however, a high frequency of recurrence is noted.

Burkitt lymphoma. BL is a germinal center-derived aggressive B-cell lymphoma with frequent *MYC* translocation. It was first described by Dr Dennis Burkitt in 1958 in Kampala, Uganda, as a common pediatric tumor involving the jaw.⁸⁹ WHO currently recognizes three different clinical variants based on geographical information and HIV status.⁹⁰ Endemic BL occurs in equatorial Africa and usually affects 4–7-year-old children, with a male predominance (2:1). Facial bones, especially jaw bones, are usually involved. Its geographical distribution overlaps with that of malaria infection.⁹¹ However, the role of malaria in the pathogenesis of BL is still unclear. Sporadic BL occurs worldwide, with a low incidence (1–2%) of all lymphomas. Young adults are usually affected, with a male:female ratio of 2–3:1. The ileocecal region is the most commonly affected site, followed by ovaries, kidneys and breasts. Immunodeficiency-associated BL specifically occurs in patients with HIV infection, congenital immunodeficiencies or posttransplantation status. All variants have a high tendency for central nervous system involvement. In endemic BL, EBV is detected in the majority of cases. However, EBV is seen in about 30% of sporadic and immunodeficiency-associated BL.

Endemic and sporadic BL typically shows a diffuse proliferation of intermediate-sized lymphoma cells, which have round-to-oval nucleus, dispersed chromatin, 2–3 discernible small nucleoli and squared-off borders for the cytoplasm. Numerous apoptotic cells with accompanying tingible-body macrophages are present, imparting a ‘starry-sky’ pattern at low magnification (Figure 6). Rare cases might show an intense granulomatous reaction. In Giemsa-stained slides, lymphoma cells have




Figure 6 Burkitt lymphoma. (a) Sheets of medium-sized cells with numerous tingible-body macrophages showing the classic starry-sky pattern. Hematoxylin and eosin, $\times 400$. (b) BCL-6 stain is positive in lymphoma cells, $\times 400$. (c) Ki-67 proliferation rate is virtually 100%, $\times 400$. (d) *In situ* hybridization for EBV shows numerous positive cells, $\times 400$.

basophilic cytoplasm with numerous cytoplasmic vacuoles. Immunodeficiency-associated BL commonly shows plasmacytic differentiation with eccentrically located nucleus, a prominent central nucleolus and more abundant cytoplasm. The lymphoma cells express B-cell markers, CD10 and BCL-6. BCL-2 expression is negative or weak and TdT is negative. The Ki-67 proliferation index is nearly 100%.

MYC rearrangement is characteristic but not a unique finding. $t(8;14)(q24;q32)$ involving the Ig heavy chain region is commonly (80%) found, followed by $t(2;8)(p12;q24)$ and $t(8;22)(q24;q11)$ involving kappa and lambda light chain loci, respectively. Cytogenetic abnormalities other than *MYC* rearrangement are rare.⁹² Gene expression profiling revealed that BL closely resembles the centroblast-rich dark zone of the germinal center, whereas DLBCL with a germinal center B-cell-like phenotype is similar to the centrocyte-rich light zone of the germinal center.⁹³ miRNA analysis found that expression of miRNAs targeted by Myc protein and miRNAs associated with NF- κ B are significantly downregulated in BL compared with DLBCL.⁹⁴ This study also showed that there was no or only minimal miRNA expression differences among the three BL variants, suggesting that the variants are the same biological entity with a different spectrum. Next-generation sequencing identified a novel loss-of-function mutation in *ID3*.^{95–97} The deleterious mutations disrupt the normal function of ID3 as a tumor suppressor and promote cell cycle progression and proliferation. Next-generation sequencing also revealed mutations in *MYC*, *TP53*, *DDX3X*, *TCF3*, *SMARCA4* and other genes. EBV⁺ BL patients show no difference in outcome from EBV⁻ BL, and EBV positivity in BL does not impact prognosis and treatment regimen selection. Patients commonly receive high-intensity, short-duration combination chemotherapy

regimens, such as DA-EPOCH-R with nearly 100% response rate and low adverse event.

Classical Hodgkin lymphoma. Hodgkin lymphoma was first described by Sir Thomas Hodgkin in 1832.⁹⁸ Hodgkin lymphomas include nodular lymphocyte-predominant Hodgkin lymphoma and CHL. CHL is further subdivided into nodular sclerosis, mixed cellularity, lymphocyte-rich and lymphocyte-depleted subtypes. CHL is characterized by the presence of scattered neoplastic HRS cells in a rich background of lymphocytes, eosinophils, plasma cells, neutrophils and histiocytes with various degrees of fibrosis. CHL has a peak of incidence in persons aged 15–35 years and a smaller second peak in an older group, aged 45–60 years. It often involves the axial lymph nodes, especially cervical nodes, and mediastinum with rare involvement of extranodal sites. CHL is usually a localized (stage I or II) disease, and the bone marrow is generally spared (<5%), except in patients with HIV infection (approximately 50%).

The classic Reed–Sternberg cells are large cells with two or more round nuclei, dispersed chromatin, prominent nucleolus and abundant basophilic cytoplasm with a perinuclear halo (Figure 7). The mononuclear variant is called the Hodgkin cell. HRS cells are characteristically positive for CD30, CD15, PAX-5 (weak/nuclear expression), MUM-1 and fascin but negative for CD3, CD20, CD45, CD68 (PG-M1), CD79a and CD138. EBV is seen in CHL, most commonly in mixed cellularity and lymphocyte depleted, followed by lymphocyte rich and nodular sclerosis. EBV-infected HRS cells usually express LMP-1 without EBNA-2 expression (phase II latency).⁹⁹ HRS single-cell PCR showed a monoclonal Ig gene rearrangement with preservation of Ig-coding capacity,




Figure 7 Classical Hodgkin lymphoma. (a) A classic binuclear Reed–Sternberg cell (center) and occasional mononuclear Hodgkin cells are intermixed with many mature-appearing lymphocytes, eosinophils, occasional plasma cells and histiocytes. Hematoxylin and eosin, $\times 400$. (b) Hodgkin Reed–Sternberg cells express CD30 with a membranous and Golgi pattern, $\times 400$. (c) A weak nuclear expression of PAX5 is seen in Hodgkin Reed–Sternberg cells. In contrast, B-lymphocytes in the background show strong expression of PAX5, $\times 400$. (d) Occasional Hodgkin Reed–Sternberg cells are positive for EBER, $\times 400$.

suggesting that the lack of B-cell markers is caused by defects in Ig gene regulatory elements.¹⁰⁰ Array-based comparative genomic hybridization applied to microdissected HRS cells revealed frequent recurrent gains in chromosomes 2p12-16, 5q15-23, 6p22, 17q12 and 19p13 and losses in Xp21, 6q23-24 and 13q22.¹⁰¹ Gene expression profiling of microdissected HRS cells showed downregulation of B-cell lineage genes, deregulation of transcription factor networks and upregulation of NF- κ B and JAK-STAT pathway-related genes and various chemokines and cytokines.¹⁰² A miRNA signature was found with 234 differentially expressed miRNAs in CHL.¹⁰³ Gene expression profiling data and miRNA data could provide additional information on risk stratification of CHL. Primary EBV⁺ HL patients show a poor survival from EBV⁻ HL; however, EBV positivity does not impact treatment regimen selection. In recurrent EBV⁺ HL with worse prognosis, adaptive immunotherapy, CD30 antibody and NF- κ B pathway inhibitors may show therapeutic promise.

Posttransplant lymphoproliferative disorders. Posttransplant lymphoproliferative disorders (PTLD) are a heterogeneous group of diseases in immunocompromised patients who are recipients of a solid organ or hematopoietic stem cell transplant.¹⁰⁴ PTLD shows a spectrum from indolent polyclonal proliferation to overtly malignant proliferation of lymphocytic or plasma cells. About 5% of PTLD are T-cell type. PTLD was first described by Doak *et al.*¹⁰⁵ in 1968 in two renal transplant recipients. The first year after transplantation has the highest risk.¹⁰⁶ Up to 2/3 of PTLD cases are associated with EBV. The risk of developing PTLD is higher in EBV-

negative recipients than in EBV-positive ones, with the highest risk in EBV⁺ donor/EBV⁻ recipients.¹⁰⁷ An increase in EBV viral load and a decrease of EBV-specific cytotoxic T-cells are associated with the development of PTLD.¹⁰⁸ Recipients of solid organ transplants, especially heart, lung, intestine or multiple organs, have higher risks of PTLD compared with patients with hematopoietic stem cell transplant. PTLD involves extranodal sites, including the tonsils, gastrointestinal tract, lung and liver as well as lymph nodes.

Morphologically, PTLD can be categorized by early lesions, polymorphic PTLD, monomorphic PTLD and CHL-type PTLD. Early lesions are further subdivided into plasmacytic hyperplasia and IM-like lesions. Plasmacytic hyperplasia is characterized by an increased number of plasma cells without effacement of tissue architecture and with residual germinal centers. IM-like lesions show the typical morphology of IM as described above. Both show minimal cytological atypia. Immunophenotype and molecular studies do not usually detect monotypic/monoclonal B-cell or plasma cell populations. Polymorphic PTLD is a destructive extranodal mass or a lesion with effacement of lymph node architecture. A polymorphic population of lymphocytes, plasma cells, immunoblasts and histiocytes is typically seen, with a variable presence of HRS-like cells (Figure 8). Of note, the full range of B-cell maturation is present, which is a morphological clue in differentiating polymorphic PTLD from monomorphic PTLD. Monotypia may or may not be seen, but the Ig gene is clonally rearranged. Monomorphic PTLD is an outright lymphoma, identical to that in immunocompetent patients. Of note, follicular lymphoma and mucosa-associated lymphoid tissue lymphoma are




Figure 8 Posttransplant lymphoproliferative disorder, polymorphic type. (a) A mixture of immunoblasts, lymphocytes, plasma cells and Hodgkin Reed–Sternberg-like cells (arrow) is present. Hematoxylin and eosin, $\times 400$. (b) CD20 stain shows a B-cell proliferation, $\times 400$. (c) *In situ* hybridization for EBV shows numerous positive cells, $\times 400$.

not designated as PTLD.¹⁰⁴ CHL-type PTLD should have classic morphology and immunophenotype and should be differentiated from polymorphic PTLD with HRS-like cells. That is, the immunophenotype for CHL-type PTLD is CD15⁺, CD20⁻, CD30⁺, CD45⁻ and PAX5 weak⁺, whereas the immunophenotype for polymorphic PTLD with HRS-like cells is usually CD15⁻, CD20⁺ and CD45⁺. EBV is almost always positive. These categories represent a spectrum of disease and can be difficult to separate in clinical practice.

Conventional karyotypic studies are correlated with morphological categories. Clonal karyotypes were seen 15–30% of polymorphic PTLD and 70–75% of monomorphic PTLD.^{109,110} Array comparative genomic hybridization detected gains at 5p13.1-p15.33 and 11p11.2-p15.5 and losses of 17p13.2-p11.2, 12p13.31-p13.3 and 12q24.33, with low frequency in monomorphic PTLD, DLBCL type.¹¹¹ Gene expression profiling of PTLD showed a clear segregation between EBV⁺ PTLD and EBV⁻ PTLD, which had minimal differences from DLBCL in immunocompetent patients. In the former, upregulated genes were related to an innate immune response induced by interferon, NK and cytotoxic T-cell markers and tolerance.¹¹² Data regarding epigenetics is rare, but hypermethylation of O⁶-methylguanine-DNA methyltransferase and death-associated protein-kinase was seen in 57% and 72% of PTLD, respectively.¹¹³ Proteomic analysis of monomorphic PTLD showed upregulated proteins in the PI3K/Akt, mitogen-activated protein kinase, protein kinase C and NF- κ B pathways.¹¹⁴ PTLD typically shows type III latency features with expression of nine EBV latency proteins (Table 2), and no optimal management approaches exist. Reduction of immunosuppression may induce durable remission in localized or indolent disease but harbor risk for the graft rejection. Variable successes are observed in aggressive type treated with combination immunochemotherapy. Immunotherapy regimens with EBV-specific cytotoxic T-lymphocytes have shown promising efficacy for prevention and treatment.

Other immunomodulator-associated lymphoproliferative disorders have been rarely reported. Similar to PTLD, iatrogenic immunodeficiency-associated lymphoproliferative disorders have been reported in patients who had been treated with purine analogue (fludarabine, pentostatin or clofarabine) with or without alemtuzumab, methotrexate, anti-tumor

necrosis factor- α agents (infliximab, adalimumab or etanercept) or other immunomodulators (daclizumab, anakinra or efalizumab) for various lymphoproliferative disorders, leukemia or autoimmune diseases.^{115–120} Association with EBV was also seen in variable numbers of such cases. A broad range of clinical manifestation has been reported, ranging from regression without treatment to an aggressive course leading to patient death. Reduction or withdrawal of immunosuppression may induce durable remission in some patients.

SUMMARY

EBV is a well-known oncogenic virus and affects about 90% of the population worldwide. Once EBV infects B-lymphocytes, it achieves latent infection as an episomal form with limited expression of a few latent genes. EBV latent proteins are well known for oncogenesis, and EBV is associated with various lymphoproliferative disorders that range broadly from benign diseases to aggressive malignant neoplasms. Oncogenic role and mechanism that EBV has vary in different clinical setting, lymphoma subtype, ethnic predisposition and genomic aberration. Optimal treatment is generally lacking in most of EBV⁺ lymphomas; novel therapeutic approaches and associated randomized clinical trials for prevention and treatment are heavily demanded. Three latency types are associated with unique entities of lymphoma pathogenesis; type I relates to selective EBNA-1 expression in BL, PEL and PBL. Immunotherapy with EBNA-1-specific CD4⁺ cytotoxic T-lymphocytes is likely effective. Type II relates to the expression of EBNA-1, LMP-1 and LMP-2 in CHL and a subset of DLBCL. Cellular therapy targeting on LMP-2 may induce clinical response. Type III associates with the expression of nine EBV proteins in PTLD, IM, LyG and DLBCL. Future studies are valuable to explore novel therapeutic agents, including miRNA-targeted therapy, EBV vaccine, specific EBV signaling pathway inhibitors and combination of EBV lytic phase induction and anti-EBV drugs.

ACKNOWLEDGEMENTS

This work was supported by the Fellowship Award at the MD Anderson Cancer Center (to CYO); the Scholarship Award at the Zhengzhou University School of Medicine (to LL); and The University of Texas MD Anderson Cancer Center Institutional Research Grant

Award, an MD Anderson Lymphoma Specialized Programs of Research Excellence (SPORE) Research Development Program Award, an MD Anderson Myeloma SPORE Research Development Program Award, MD Anderson Collaborative Research Funds with High-Throughput Molecular Diagnostics, Gilead Science, Adaptive Biotechnologies and Roche Molecular Systems (to KHY). This work was also partially supported by National Cancer Institute and National Institutes of Health grants (R01CA138688, 1RC1CA146299, P50CA136411 and P50CA142509) and by the MD Anderson Cancer Center Support grant CA016672.

- 1 Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. *Lancet* 1964; **1**: 702–703.
- 2 Yao QY, Rickinson AB, Epstein MA. A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals. *Int J Cancer* 1985; **35**: 35–42.
- 3 Castillo JJ, Reagan JL, Bishop KD, Apor E. Viral lymphomagenesis: from pathophysiology to the rationale for novel therapies. *Br J Haematol* 2014; **165**: 300–315.
- 4 Sixbey JW, Nedrud JG, Raab-Traub N, Hanes RA, Pagano JS. Epstein-Barr virus replication in oropharyngeal epithelial cells. *New Engl J Med* 1984; **310**: 1225–1230.
- 5 Fingerth JD, Weis JJ, Tedder TF, Strominger JL, Biro PA, Fearon DT. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. *Proc Natl Acad Sci USA* 1984; **81**: 4510–4514.
- 6 Li Q, Spriggs MK, Kovats S, Turk SM, Comeau MR, Nepom B *et al*. Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes. *J Virol* 1997; **71**: 4657–4662.
- 7 Given D, Yee D, Griem K, Kieff E. DNA of Epstein-Barr virus. V. Direct repeats of the ends of Epstein-Barr virus DNA. *J Virol* 1979; **30**: 852–862.
- 8 Yates J, Warren N, Reisman D, Sugden B. A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. *Proc Natl Acad Sci USA* 1984; **81**: 3806–3810.
- 9 Johannsen E, Koh E, Mosialos G, Tong X, Kieff E, Grossman SR. Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by κ and PU.1. *J Virol* 1995; **69**: 253–262.
- 10 Kieff ED, Rickinson AB (eds). *Epstein-Barr Virus and Its Replication*. Lippincott Williams and Wilkins: Philadelphia, PA, USA, 2006.
- 11 Le Roux A, Kerdiles B, Walls D, Dedieu JF, Perricaudet M. The Epstein-Barr virus determined nuclear antigens EBNA-3A, -3B, and -3C repress EBNA-2-mediated transactivation of the viral terminal protein 1 gene promoter. *Virology* 1994; **205**: 596–602.
- 12 Kulwicht W, Edwards RH, Davenport EM, Baskar JF, Godfrey V, Raab-Traub N. Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. *Proc Natl Acad Sci USA* 1998; **95**: 11963–11968.
- 13 Uchida J, Yasui T, Takaoka-Shichijo Y, Muraoka M, Kulwicht W, Raab-Traub N *et al*. Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. *Science* 1999; **286**: 300–303.
- 14 Liebowitz D. Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. *New Engl J Med* 1998; **338**: 1413–1421.
- 15 Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R *et al*. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. *Cell* 1991; **65**: 1107–1115.
- 16 Fries KL, Miller WE, Raab-Traub N. Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene. *J Virol* 1996; **70**: 8653–8659.
- 17 Dawson CW, Tramontanis G, Eliopoulos AG, Young LS. Epstein-Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase/Akt pathway to promote cell survival and induce actin filament remodeling. *J Biol Chem* 2003; **278**: 3694–3704.
- 18 Roberts ML, Cooper NR. Activation of a ras-MAPK-dependent pathway by Epstein-Barr virus latent membrane protein 1 is essential for cellular transformation. *Virology* 1998; **240**: 93–99.
- 19 Eliopoulos AG, Waites ER, Blake SM, Davies C, Murray P, Young LS. TRAF1 is a critical regulator of JNK signaling by the TRAF-binding domain of the Epstein-Barr virus-encoded latent infection membrane protein 1 but not CD40. *J Virol* 2003; **77**: 1316–1328.
- 20 Everly DN Jr, Mainou BA, Raab-Traub N. Induction of Id1 and Id3 by latent membrane protein 1 of Epstein-Barr virus and regulation of p27/Kip and cyclin-dependent kinase 2 in rodent fibroblast transformation. *J Virol* 2004; **78**: 13470–13478.
- 21 Laux G, Perricaudet M, Farrell PJ. A spliced Epstein-Barr virus gene expressed in immortalized lymphocytes is created by circularization of the linear viral genome. *EMBO J* 1988; **7**: 769–774.
- 22 Brinkmann MM, Schulz TF. Regulation of intracellular signalling by the terminal membrane proteins of members of the Gammaherpesvirinae. *J Gen Virol* 2006; **87**: 1047–1074.
- 23 Middeldorp JM, Brink AA, van den Brule AJ, Meijer CJ. Pathogenic roles for Epstein-Barr virus (EBV) gene products in EBV-associated proliferative disorders. *Crit Rev Oncol Hematol* 2003; **45**: 1–36.
- 24 Miller CL, Burkhardt AL, Lee JH, Stealey B, Longnecker R, Bolen JB *et al*. Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. *Immunity* 1995; **2**: 155–166.
- 25 Bultema R, Longnecker R, Swanson-Mungerson M. Epstein-Barr virus LMP2A accelerates MYC-induced lymphomagenesis. *Oncogene* 2009; **28**: 1471–1476.
- 26 Portis T, Longnecker R. Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/Akt pathway. *Oncogene* 2004; **23**: 8619–8628.
- 27 Fish K, Chen J, Longnecker R. Epstein-Barr virus latent membrane protein 2A enhances MYC-driven cell cycle progression in a mouse model of B lymphoma. *Blood* 2014; **123**: 530–540.
- 28 Rechsteiner MP, Bernasconi M, Berger C, Nadal D. Role of latent membrane protein 2 isoforms in Epstein-Barr virus latency. *Trends Microbiol* 2008; **16**: 520–527.
- 29 Howe JG, Steitz JA. Localization of Epstein-Barr virus-encoded small RNAs by in situ hybridization. *Proc Natl Acad Sci USA* 1986; **83**: 9006–9010.
- 30 Hamilton-Dutoit SJ, Raphael M, Audouin J, Diebold J, Lisse I, Pedersen C *et al*. In situ demonstration of Epstein-Barr virus small RNAs (EBER 1) in acquired immunodeficiency syndrome-related lymphomas: correlation with tumor morphology and primary site. *Blood* 1993; **82**: 619–624.
- 31 Pfeffer S, Zavolan M, Grassler FA, Chien M, Russo JJ, Ju J *et al*. Identification of virus-encoded microRNAs. *Science* 2004; **304**: 734–736.
- 32 Xing L, Kieff E. Epstein-Barr virus BHRF1 micro- and stable RNAs during latency III and after induction of replication. *J Virol* 2007; **81**: 9967–9975.
- 33 Chen H, Huang J, Wu FY, Liao G, Hutt-Fletcher L, Hayward SD. Regulation of expression of the Epstein-Barr virus BamHI-A rightward transcripts. *J Virol* 2005; **79**: 1724–1733.
- 34 Barth S, Pfuhl T, Mamiani A, Ehse C, Roemer K, Kremmer E *et al*. Epstein-Barr virus-encoded microRNA miR-BART2 down-regulates the viral DNA polymerase BALF5. *Nucleic Acids Res* 2008; **36**: 666–675.
- 35 Iizasa H, Wulff BE, Alla NR, Maragkakis M, Megraw M, Hatzigeorgiou A *et al*. Editing of Epstein-Barr virus-encoded BART6 microRNAs controls their dicer targeting and consequently affects viral latency. *J Biol Chem* 2010; **285**: 33358–33370.
- 36 Lung RW, Tong JH, Sung YM, Leung PS, Ng DC, Chau SL *et al*. Modulation of LMP2A expression by a newly identified Epstein-Barr virus-encoded microRNA miR-BART22. *Neoplasia* 2009; **11**: 1174–1184.
- 37 Skalsky RL, Corcoran DL, Gottwein E, Frank CL, Kang D, Hafner M *et al*. The viral and cellular microRNA targetome in lymphoblastoid cell lines. *PLoS Pathog* 2012; **8**: e1002484.
- 38 Seto E, Moosmann A, Gromminger S, Walz N, Grundhoff A, Hammerschmidt W. Micro RNAs of Epstein-Barr virus promote cell cycle progression and prevent apoptosis of primary human B cells. *PLoS Pathog* 2010; **6**: e1001063.
- 39 Choy EY, Siu KL, Kok KH, Lung RW, Tsang CM, To KF *et al*. An Epstein-Barr virus-encoded microRNA targets PUMA to promote host cell survival. *J Exp Med* 2008; **205**: 2551–2560.
- 40 Gatto G, Rossi A, Rossi D, Kroening S, Bonatti S, Mallardo M. Epstein-Barr virus latent membrane protein 1 trans-activates miR-155 transcription through the NF- κ B pathway. *Nucleic Acids Res* 2008; **36**: 6608–6619.

- 41 Forte E, Salinas RE, Chang C, Zhou T, Linnstaedt SD, Gottwein E et al. The Epstein-Barr virus (EBV)-induced tumor suppressor microRNA MiR-34a is growth promoting in EBV-infected B cells. *J Virol* 2012; **86**: 6889–6898.
- 42 Rosato P, Anastasiadou E, Garg N, Lenze D, Boccellato F, Vincenti S et al. Differential regulation of miR-21 and miR-146a by Epstein-Barr virus-encoded EBNA2. *Leukemia* 2012; **26**: 2343–2352.
- 43 Dojcinov SD, Venkataraman G, Raffeld M, Pittaluga S, Jaffe ES. EBV positive mucocutaneous ulcer—a study of 26 cases associated with various sources of immunosuppression. *Am J Surg Pathol* 2010; **34**: 405–417.
- 44 Cohen JI, Jaffe ES, Dale JK, Pittaluga S, Heslop HE, Rooney CM et al. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. *Blood* 2011; **117**: 5835–5849.
- 45 Straus SE. The chronic mononucleosis syndrome. *J Infect Dis* 1988; **157**: 405–412.
- 46 Cohen JI, Kimura H, Nakamura S, Ko YH, Jaffe ES. Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008. *Ann Oncol* 2009; **20**: 1472–1482.
- 47 Kimura H, Morishima T, Kanegane H, Ohga S, Hoshino Y, Maeda A et al. Prognostic factors for chronic active Epstein-Barr virus infection. *J Infect Dis* 2003; **187**: 527–533.
- 48 Du MQ, Diss TC, Liu H, Ye H, Hamoudi RA, Cabecadas J et al. KSHV- and EBV-associated germinotropic lymphoproliferative disorder. *Blood* 2002; **100**: 3415–3418.
- 49 Nakamura S, Jaffe ES, Swerdlow SH (eds). *EBV Positive Diffuse Large B-Cell Lymphoma of the Elderly*. International Agency for Research on Cancer (IARC): Lyon, France, 2008.
- 50 Oyama T, Ichimura K, Suzuki R, Suzumiya J, Ohshima K, Yatabe Y et al. Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients. *Am J Surg Pathol* 2003; **27**: 16–26.
- 51 Ok CY, Papatomas TG, Medeiros LJ, Young KH. EBV-positive diffuse large B-cell lymphoma of the elderly. *Blood* 2013; **122**: 328–340.
- 52 Ok CY, Li L, Xu-Monette ZY, Visco C, Tzankov A, Manyam GC et al. Prevalence and clinical implications of Epstein-Barr virus infection in *de novo* diffuse large B-cell lymphoma in Western countries. *Clin Cancer Res* 2014; **20**: 2338–2349.
- 53 Hofscheier A, Ponciano A, Bonzheim I, Adam P, Lome-Maldonado C, Vela T et al. Geographic variation in the prevalence of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly: a comparative analysis of a Mexican and a German population. *Mod Pathol* 2011; **24**: 1046–1054.
- 54 Kuze T, Nakamura N, Hashimoto Y, Sasaki Y, Abe M. The characteristics of Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma: comparison between EBV(+) and EBV(-) cases in Japanese population. *Jpn J Cancer Res* 2000; **91**: 1233–1240.
- 55 Oyama T, Yamamoto K, Asano N, Oshiro A, Suzuki R, Kagami Y et al. Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. *Clin Cancer Res* 2007; **13**: 5124–5132.
- 56 Park S, Lee J, Ko YH, Han A, Jun HJ, Lee SC et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. *Blood* 2007; **110**: 972–978.
- 57 Hoeller S, Tzankov A, Pileri SA, Went P, Dirnhofer S. Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly patients is rare in Western populations. *Hum Pathol* 2010; **41**: 352–357.
- 58 Montes-Moreno S, Odqvist L, Diaz-Perez JA, Lopez AB, de Villambrosia SG, Mazorra F et al. EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor- κ B activation. *Mod Pathol* 2012; **25**: 968–982.
- 59 Chan JKC, Aozasa K, Gaulard P (eds). *DLBCL Associated with Chronic Inflammation*. IARC: Lyon, France, 2008.
- 60 Iuchi K, Ichimiya A, Akashi A, Mizuta T, Lee YE, Tada H et al. Non-Hodgkin's lymphoma of the pleural cavity developing from long-standing pyothorax. *Cancer* 1987; **60**: 1771–1775.
- 61 Nakatsuka S, Yao M, Hoshida Y, Yamamoto S, Iuchi K, Aozasa K. Pyothorax-associated lymphoma: a review of 106 cases. *J Clin Oncol* 2002; **20**: 4255–4260.
- 62 Petitjean B, Jardin F, Joly B, Martin-Garcia N, Tilly H, Picqueton JM et al. Pyothorax-associated lymphoma: a peculiar clinicopathologic entity derived from B cells at late stage of differentiation and with occasional aberrant dual B- and T-cell phenotype. *Am J Surg Pathol* 2002; **26**: 724–732.
- 63 Yamato H, Ohshima K, Suzumiya J, Kikuchi M. Evidence for local immunosuppression and demonstration of c-myc amplification in pyothorax-associated lymphoma. *Histopathology* 2001; **39**: 163–171.
- 64 Hongyo T, Kurooka M, Taniguchi E, Iuchi K, Nakajima Y, Aozasa K et al. Frequent p53 mutations at dipyrimidine sites in patients with pyothorax-associated lymphoma. *Cancer Res* 1998; **58**: 1105–1107.
- 65 Nishi M, Tomita Y, Nakatsuka S, Takakuwa T, Izuka N, Hoshida Y et al. Distinct pattern of gene expression in pyothorax-associated lymphoma (PAL), a lymphoma developing in long-standing inflammation. *Cancer Sci* 2004; **95**: 828–834.
- 66 Stein H, Harris NL, Campo E (eds). *Plasmablastic Lymphoma*. IARC: Lyon, France, 2008.
- 67 Delecluse HJ, Anagnostopoulos I, Dallenbach F, Hummel M, Marafioti T, Schneider U et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. *Blood* 1997; **89**: 1413–1420.
- 68 Castillo J, Pantanowitz L, Dezube BJ. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. *Am J Hematol* 2008; **83**: 804–809.
- 69 Teruya-Feldstein J, Chiao E, Filippa DA, Lin O, Comenzo R, Coleman M et al. CD20-negative large-cell lymphoma with plasmablastic features: a clinically heterogeneous spectrum in both HIV-positive and -negative patients. *Ann Oncol* 2004; **15**: 1673–1679.
- 70 Hsi ED, Lorschach RB, Fend F, Dogan A. Plasmablastic lymphoma and related disorders. *Am J Clin Pathol* 2011; **136**: 183–194.
- 71 Isaacson PG, Campo E, Harris NL (eds). *Large B-Cell Lymphoma Arising in HHV8-Associated Multicentric Castlemans Disease*. IARC: Lyon, France, 2008.
- 72 Valera A, Balague O, Colomo L, Martinez A, Delabie J, Tadesse-Heath L et al. *IG/ MYC* rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. *Am J Surg Pathol* 2010; **34**: 1686–1694.
- 73 Said J, Cesarman E (eds). *Primary Effusion Lymphoma*. IARC: Lyon, France, 2008.
- 74 Nador RG, Cesarman E, Chadburn A, Dawson DB, Ansari MQ, Sald J et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. *Blood* 1996; **88**: 645–656.
- 75 Chadburn A, Hyjek E, Mathew S, Cesarman E, Said J, Knowles DM. KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma. *Am J Surg Pathol* 2004; **28**: 1401–1416.
- 76 Jones D, Ballestas ME, Kaye KM, Gulizia JM, Winters GL, Fletcher J et al. Primary-effusion lymphoma and Kaposi's sarcoma in a cardiac-transplant recipient. *New Engl J Med* 1998; **339**: 444–449.
- 77 Said JW, Tasaka T, Takeuchi S, Asou H, de Vos S, Cesarman E et al. Primary effusion lymphoma in women: report of two cases of Kaposi's sarcoma herpes virus-associated effusion-based lymphoma in human immunodeficiency virus-negative women. *Blood* 1996; **88**: 3124–3128.
- 78 Cobo F, Hernandez S, Hernandez L, Pinyol M, Bosch F, Esteve J et al. Expression of potentially oncogenic HHV-8 genes in an EBV-negative primary effusion lymphoma occurring in an HIV-seronegative patient. *J Pathol* 1999; **189**: 288–293.
- 79 Horenstein MG, Nador RG, Chadburn A, Hyjek EM, Inghirami G, Knowles DM et al. Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8. *Blood* 1997; **90**: 1186–1191.
- 80 Pan ZG, Zhang QY, Lu ZB, Quinto T, Rozenvald IB, Liu LT et al. Extracavitary KSHV-associated large B-cell lymphoma: a distinct entity or a subtype of primary effusion lymphoma? Study of 9 cases and review of an additional 43 cases. *Am J Surg Pathol* 2012; **36**: 1129–1140.
- 81 Mullaney BP, Ng VL, Herndier BG, McGrath MS, Pallavicini MG. Comparative genomic analyses of primary effusion lymphoma. *Arch Pathol Lab Med* 2000; **124**: 824–826.
- 82 Klein U, Gloghini A, Gaidano G, Chadburn A, Cesarman E, Dalla-Favera R et al. Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. *Blood* 2003; **101**: 4115–4121.
- 83 Liebow AA, Carrington CR, Friedman PJ. Lymphomatoid granulomatosis. *Hum Pathol* 1972; **3**: 457–558.
- 84 Pittaluga S, Wilson WH, Jaffe ES (eds). *Lymphomatoid Granulomatosis*. IARC: Lyon, France, 2008.

- 85 Beaty MW, Toro J, Sorbara L, Stern JB, Pittaluga S, Raffeld M *et al*. Cutaneous lymphomatoid granulomatosis: correlation of clinical and biologic features. *Am J Surg Pathol* 2001; **25**: 1111–1120.
- 86 Tanriere P, Thivolet-Bejui F, Vitrey D, Isaac S, Loire R, Cordier JF *et al*. Lymphomatoid granulomatosis—a report on four cases: evidence for B phenotype of the tumoral cells. *Eur Respir J* 1998; **12**: 102–106.
- 87 Katzenstein AL, Carrington CB, Liebow AA. Lymphomatoid granulomatosis: a clinicopathologic study of 152 cases. *Cancer* 1979; **43**: 360–373.
- 88 Guinee D Jr., Jaffe E, Kingma D, Fishback N, Wallberg K, Krishnan J *et al*. Pulmonary lymphomatoid granulomatosis. Evidence for a proliferation of Epstein-Barr virus infected B-lymphocytes with a prominent T-cell component and vasculitis. *Am J Surg Pathol* 1994; **18**: 753–764.
- 89 Burkitt D. A sarcoma involving the jaws in African children. *Br J Surg* 1958; **46**: 218–223.
- 90 Leoncini L, Raphael M, Stein H, Harris NL, Jaffe E, Kluijn PM (eds). *Burkitt Lymphoma*. IARC: Lyon, France, 2008.
- 91 Morrow RH, Kisuule A, Pike MC, Smith PG. Burkitt's lymphoma in the Mengo Districts of Uganda: epidemiologic features and their relationship to malaria. *J Natl Cancer Inst* 1976; **56**(3): 479–483.
- 92 Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF *et al*. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. *New Engl J Med* 2006; **354**: 2419–2430.
- 93 Victora GD, Dominguez-Sola D, Holmes AB, Deroubaix S, Dalla-Favera R, Nussenzweig MC. Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas. *Blood* 2012; **120**: 2240–2248.
- 94 Lenze D, Leoncini L, Hummel M, Volinia S, Liu CG, Amato T *et al*. The different epidemiologic subtypes of Burkitt lymphoma share a homogenous micro RNA profile distinct from diffuse large B-cell lymphoma. *Leukemia* 2011; **25**: 1869–1876.
- 95 Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M *et al*. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. *Nature* 2012; **490**: 116–120.
- 96 Richter J, Schlessner M, Hoffmann S, Kreuz M, Leich E, Burkhardt B *et al*. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. *Nat Genet* 2012; **44**: 1316–1320.
- 97 Love C, Sun Z, Jima D, Li G, Zhang J, Miles R *et al*. The genetic landscape of mutations in Burkitt lymphoma. *Nat Genet* 2012; **44**: 1321–1325.
- 98 Hodgkin T. On some morbid appearances of the absorbent glands and spleen. *Med Chir Trans* 1832; **17**: 68–114.
- 99 Delsol G, Brousset P, Chittal S, Rigal-Huguet F. Correlation of the expression of Epstein-Barr virus latent membrane protein and *in situ* hybridization with biotinylated BamHI-W probes in Hodgkin's disease. *Am J Pathol* 1992; **140**: 247–253.
- 100 Marafioti T, Hummel M, Foss HD, Laumen H, Korbjuhn P, Anagnostopoulos I *et al*. Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. *Blood* 2000; **95**: 1443–1450.
- 101 Hartmann S, Martin-Subero JI, Gesk S, Husken J, Giefing M, Nagel I *et al*. Detection of genomic imbalances in microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma by array-based comparative genomic hybridization. *Haematologica* 2008; **93**: 1318–1326.
- 102 Steidl C, Diepstra A, Lee T, Chan FC, Farinha P, Tan K *et al*. Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma. *Blood* 2012; **120**: 3530–3540.
- 103 Sanchez-Espiridon B, Martin-Moreno AM, Montalban C, Figueroa V, Vega F, Younes A *et al*. MicroRNA signatures and treatment response in patients with advanced classical Hodgkin lymphoma. *Br J Haematol* 2013; **162**: 336–347.
- 104 Swerdlow SH, Webber SA, Chadburn A, Ferry JA (eds). *Post-transplant Lymphoproliferative Disorders*. IARC: Lyon, France, 2008.
- 105 Doak PB, Montgomerie JZ, North JD, Smith F. Reticulum cell sarcoma after renal homotransplantation and azathioprine and prednisone therapy. *Br Med J* 1968; **4**: 746–748.
- 106 Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. *Am J Transplant* 2004; **4**: 222–230.
- 107 McDonald RA, Smith JM, Ho M, Lindblad R, Ikle D, Grimm P *et al*. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. *Am J Transplant* 2008; **8**: 984–989.
- 108 Sebelin-Wulf K, Nguyen TD, Oertel S, Papp-Vary M, Trappe RU, Schulzki A *et al*. Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD. *Transpl Immunol* 2007; **17**: 203–210.
- 109 Vakiani E, Nandula SV, Subramaniam S, Keller CE, Alobeid B, Murty VV *et al*. Cytogenetic analysis of B-cell posttransplant lymphoproliferations validates the World Health Organization classification and suggests inclusion of florid follicular hyperplasia as a precursor lesion. *Hum Pathol* 2007; **38**: 315–325.
- 110 Djokic M, Le Beau MM, Swinnen LJ, Smith SM, Rubin CM, Anastasi J *et al*. Post-transplant lymphoproliferative disorder subtypes correlate with different recurring chromosomal abnormalities. *Genes Chromosomes Cancer* 2006; **45**: 313–318.
- 111 Rinaldi A, Kwee I, Poretti G, Mensah A, Pruner G, Capello D *et al*. Comparative genome-wide profiling of post-transplant lymphoproliferative disorders and diffuse large B-cell lymphomas. *Br J Haematol* 2006; **134**: 27–36.
- 112 Morscio J, Dierickx D, Ferreira JF, Herreman A, Van Loo P, Bittoun E *et al*. Gene expression profiling reveals clear differences between EBV-positive and EBV-negative posttransplant lymphoproliferative disorders. *Am J Transplant* 2013; **13**: 1305–1316.
- 113 Rossi D, Gaidano G, Ghoghini A, Deambroggi C, Franceschetti S, Berra E *et al*. Frequent aberrant promoter hypermethylation of O⁶-methylguanine-DNA methyltransferase and death-associated protein kinase genes in immunodeficiency-related lymphomas. *Br J Haematol* 2003; **123**: 475–478.
- 114 Alsayed Y, Leleu X, Leontovich A, Oton AB, Melhem M, George D *et al*. Proteomics analysis in post-transplant lymphoproliferative disorders. *Eur J Haematol* 2008; **81**: 298–303.
- 115 Abruzzo LV, Rosales CM, Medeiros LJ, Vega F, Luthra R, Manning JT *et al*. Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms. *Am J Surg Pathol* 2002; **26**: 630–636.
- 116 Ghobrial IM, Otteman LA, White WL. An EBV-positive lymphoproliferative disorder after therapy with alemtuzumab. *New Engl J Med* 2003; **349**: 2570–2572; discussion 2570–2572.
- 117 Sohani AR, Ferry JA, Chang PS, Abramson JS. Epstein-Barr virus-positive diffuse large B-cell lymphoma during therapy with alemtuzumab for T-cell prolymphocytic leukemia. *J Clin Oncol* 2010; **28**: e69–e72.
- 118 Hasserjian RP, Chen S, Perkins SL, de Leval L, Kinney MC, Barry TS *et al*. Immunomodulator agent-related lymphoproliferative disorders. *Mod Pathol* 2009; **22**: 1532–1540.
- 119 Kikuchi K, Miyazaki Y, Tanaka A, Shigematu H, Kojima M, Sakashita H *et al*. Methotrexate-related Epstein-Barr virus (EBV)-associated lymphoproliferative disorder—so-called 'Hodgkin-like lesion'—of the oral cavity in a patient with rheumatoid arthritis. *Head Neck Pathol* 2010; **4**: 305–311.
- 120 Bhamidipati PK, Jabbar E, Konoplev S, Estrov Z, Cortes J, Daver N. Epstein-Barr virus-induced CD30-positive diffuse large B-cell lymphoma in a patient with mixed-phenotypic leukemia treated with clofarabine. *Clin Lymphoma Myeloma Leuk* 2013; **13**: 342–346.



This work is licensed under a Creative Commons Attribution 3.0 Unported License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/3.0/>